Myriad Genetics (MYGN) Beat But Not By Enough, Mizuho Says; PT to $34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Leerink Partners Remains Sidelined on Myriad Genetics (MYGN) - PT to $41
May 4, 2016 7:44 AM EDTLeerink Partners maintained a Market Perform rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $41.00 (from $44.00), following the company's 3Q earnings report. MYGN reported revenue of $190.5M, beating expectations of $185M by ~3%. Management guided F4Q revenue in the... More
Myriad Genetics (MYGN) Tops Q3 EPS by 3c, Offers Q4 & FY Guidance
May 3, 2016 4:07 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.41, $0.03 better than the analyst estimate of $0.38. Revenue for the quarter came in at $190.5 million versus the consensus estimate of $184.92 million.
GUIDANCE:
Myriad Genetics sees Q4 2016 EPS of $0.36-$0.38, versus the consensus of... More
